Analysis Of The Adverse Effects Of High Dose Methotrexate In The Treatment Of Acute Lymphoblastic Leukemia

Objective: Effect of high dose methotrexate(HDMTX) therapy for acute lymphoblasticleukemia, blood concentration of methotrexate methotrexate and clinical features ofdrug-induced adverse drug reaction, and the study of reduced folate carrier (RFC1) geneA80G polymorphism in acute lymphoblastic leukemia (ALL) the use of high-dosemethotrexate (HDMTX) on adverse reaction of chemotherapy in the. Methods: Analysisof43patients with acute lymphocytic leukemia patients received standard are high-dosemethotrexate chemotherapy clinical material, observe side effects. Results:In43patientsreceiving high-dose methotrexate chemotherapy patients with bone marrow suppression,gastrointestinal reactions (7/43)(14/43), oral ulcer (10/43), hepatic dysfunction (8/43),impaired renal function (2/43), as a common adverse drug reaction in clinical. Afterchemotherapy,43patients24hours blood concentration of methotrexate (3.42mmol/L9.30),with calcium folinate (CF) rescued after48hours, the measured average plasmaconcentration of0.34(0.69) mmol/L, average72hours blood concentration in0(0) mmol/L.Conclusion: The use of high-dose methotrexate treatment， attention should be paid toalkalization， water sufficient， and the correct use of leucovorin rescue in order to ensurethe key elements of high-dose methotrexate chemotherapy smoothly. Occurrence ofmethotrexate toxicity should arouse more attention in clinic， early detection ofsymptomatic treatment， to minimize the adverse reaction.